Company intelligence / Profile preview
NKGen Biotech
Santa Ana, California, United States
- Ownership
- Public · NKGN
- Employees
- ~63
- Development stage
- Other
01
Overview
NKGen Biotech's lead asset, troculeucel (SNK01), has demonstrated cessation of disease progression and/or cognitive improvement in over 90% of Alzheimer’s patients treated to date and is in Phase 2 trials for moderate Alzheimer’s disease. The company has completed Phase 1/2a trials in advanced refractory solid tumors and non-small cell lung cancer, with further allogeneic and CAR-NK candidates advancing toward clinical studies.[10][2][8]
- Therapeutic areas
- OncologyNeurology
- Modalities
- NK cell therapyCAR-NK cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on NKGen Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKGen Biotech.